Optic IconOptic Logo
|
SearchCollectionsBenchmarks

IMM2510

1 clinical trial

2 abstracts

1 indication

Indication
Cancer
Abstract
IMM2510, an anti-PD-L1/VEGF bispecific antibody fusion protein, in patients with advanced solid tumors: A phase I dose-escalation study.
Org: Fudan University Shanghai Cancer Center, Zhejiang Cancer Hospital, Chinese Academy of Sciences, Shandong Provincial Institute of Cancer Prevention and Treatment, The First Affiliated Hospital of Henan University of Science and Technology, ImmuneOnco Biopharmaceuticals (Shanghai) Inc., Shanghai, China,
Clinical trial
IMM2510, a Multi-Center, Open-Label, Dose Escalation and Cohort Expansion Phase I Clinical Study for Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2023-12-01
Abstract
Preliminary results of a phase I dose escalation study of IMM2510, a PD-L1 and VEGF bispecific fusion protein, in patients with advanced tumors.
Org: Zhejiang Cancer Hospital, Chinese Academy of Sciences, Fudan University Shanghai Cancer Center, Shandong Provincial Institute of Cancer Prevention and Treatment, The First Affiliated Hospital of Henan University of Science and Technology, ImmuneOnco Biopharmaceuticals (Shanghai) Inc., Shanghai, China,